Eikon Therapeutics, a Phase 2 biotech developing in-licensed therapies for immuno-responsive cancers, raised $381 million in an upsized IPO by offering 21.2 million shares at $18, the high end of the range of $16 to $18. The company originally planned to offer 17.6 million shares.
Eikon Therapeutics plans to list on the Nasdaq under the symbol EIKN. J.P. Morgan, Morgan Stanley, BofA Securities, Cantor Fitzgerald, and Mizuho Securities acted as joint bookrunners on the deal.
